Morganella morganni is a facultative anaerobic Gramnegative bacillus. Septic arthritis due to Morganella sp. is rare, but when it occurs, it usually presents in immunosuppressed individuals [1] . Immune reconstitution inflammatory syndrome (IRIS) is a well-known complication in HIV, but seldom seen in HSCT; bacterial arthritis IRIS, has rarely been described [2] [3] [4] [5] .
We describe a 19-year old woman who received a haploidentical HSCT for acute myeloid leukemia, 4 years prior. She developed chronic-graft-vs.-host disease (GVHD) with skin and lung involvement that required continued immunosuppresive therapy. A year later, presented with pain on the left hip, inability to walk and fever. Imaging of the hip, showed effusion in the acetabular space and changes suggestive of avascular necrosis. Cultures obtained by surgical drainage of the fluid and tissue grew M. morganni. She received directed antibiotic treatment with partial improvement. One month later, while still on antibiotic treatment, presented again right shoulder pain and signs of systemic inflammatory response syndrome. Septic arthritis again due to M. morganni was documented in the right shoulder and osteomyelitis in the left hip. As a result, she underwent left femoral head resection and a right shoulder surgical lavage. All her immunosuppression was stopped. A few days later she still had signs of septic arthritis of the shoulder, and now developed right knee pain and edema, microbial cultures grew M. morganni. Infective endocarditis was ruled out with transthoracic and transesophageal echocardiogram; multiple blood cultures were all negative.
During her 11-month hospitalization she presented numerous new episodes (every 2-3 weeks) of arthritis (pain, erythema, increase in volume) of the right shoulder and/or knee, imaging compatible with septic arthritis (Fig. 1 ), but no growth on subsequent microbial cultures, even though drainage (either by surgery or interventional radiology) would yield abundant purulent fluid and resolution of her symptoms right after the drainage. Given that her symptoms recurred so frequently, despite optimized surgical and antimicrobial management, and that her immune suppression that been completely stopped several months prior, when there was evidence of uncontrolled infection, inflammatory reconstitution immune syndrome was considered and sirolimus was initiated. No corticosteroids were started due to the degree of avascular necrosis she already had.
Three weeks after the initiation of treatment, the patient was finally discharged from the hospital, with limitation in the mobility of the right shoulder and the left hip. At followup, 8 months after her discharge, there has been no recurrence of the arthritis, and has not required any new surgical intervention, despite no antimicrobial treatment. She continues on low-dose sirolimus.
The immune response is vital against infection; however, a disproportionate response can lead to pathologic inflammation well beyond the ideal protective immunity. This exaggerated response, known as IRIS, has been well characterized in patients with HIV infection, in whom antiretroviral treatment can lead to a rapid recovery of functional T cells, in the setting of opportunistic infections [2, 3] . Although IRIS has been described in transplant recipients, it is a poorly understood phenomenon, believed to be due to a reversal from an anti-inflammatory response (Tregs and Th2 cells) to a proinflammatory response (Th17 Alvaro López-Iñigue, Alejandro Carrera-Villanueva, Jennifer CuellarRodriguez, and Eucario León Rodríguez contributed equally to this work. Bacterial arthritis has rarely been described as a cause of IRIS in HIV individuals, and never in transplant recipients. On the other hand, although it is possible that this is a manifestation of GVHD (peripheral blood chimerism 100% donor), GVHD rarely if ever, presents solely as articular disease, and in particular in our patient she experienced no reactivation of her skin or lung GVHD.
Although the standard treatment for IRIS in HIV and other immunosuppressive states has been corticosteroids, we decided against it, due to her underlying bone damage. Treatment with sirolimus has not routinely been used for this indication, although widely used for GVHD, and occasionally for rejection in SOT. Sirolimus is an MTOR inhibitor, which inhibits the activation of Th1, and Th17 cells, while increasing the generation of Tregs. In animal models of arthritis it leads to a decrease in histopathologic changes of bone erosion, ankylosis, and serum and joint fluid levels of inflammatory cytokines [6] [7] [8] [9] .
Optimal management of iatrogenic immunosuppression in the setting of infection is complicated. Clinicians have to be mindful of the delicate balance that leads to successful eradication of invading pathogens without self-damage in patients that have a non-quantifiable immune defect, and keep the diagnosis of IRIS in the differential diagnosis of a worsening or non-resolving "infection". A delay in diagnosis can lead to organ damage and disability. Diagnosis and management of IRIS in transplant recipients constitutes a great challenge, which requires increased awareness of the disease [4] . 
